NASDAQ:SHPG - Shire Stock Price, Price Target & More

$164.37 +3.63 (+2.26 %)

(As of 04/22/2018 04:00 PM ET)

Previous Close$164.37

Today's Range$159.81 - $166.00

52-Week Range$123.73 - $192.15

Volume4.28 million shs

Average Volume1.74 million shs

Market Capitalization$49.96 billion

P/E Ratio10.85

Dividend Yield0.64%

Beta1.31

About Shire (NASDAQ:SHPG)

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE, ADYNOVATE/ADYNOVI, and OBIZUR for the treatment of hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand disease; FEIBA to treat hemophilia A and B patients with inhibitors; ELAPRASE to treat hunter syndrome; REPLAGAL for fabry disease; and VPRIV to treat type 1 Gaucher disease. The company's marketed products also comprise VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR and MYDAYIS to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of CINRYZE and FIRAZYR for the treatment of hereditary angioedema; FOSRENOL to treat hyperphosphatemia; LIALDA/MEZAVANT and PENTASA for ulcerative colitis; GATTEX/REVESTIVE for the treatment of short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA for the treatment of dry eye disease. The company markets its products through wholesalers, distributors, and pharmacies. It has collaborative and other licensing arrangements with Rani Therapeutics LLC; Parion Sciences Inc.; Pfizer Inc.; Precision BioSciences Inc.; Symphogen; and Ipsen Bioscience Inc. The company was founded in 1986 and is headquartered in Dublin, Ireland.

Receive SHPG News and Ratings via Email

Sign-up to receive the latest news and ratings for SHPG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:SHPG

CUSIPN/A

Webwww.shire.com

Phone353-1609-6000

Debt

Debt-to-Equity Ratio0.46%

Current Ratio0.97%

Quick Ratio0.55%

Price-To-Earnings

Trailing P/E Ratio10.85

Forward P/E Ratio10.81

P/E Growth1.29

Sales & Book Value

Annual Sales$15.16 billion

Price / Sales3.30

Cash Flow$22.7030 per share

Price / Cash7.24

Book Value$119.43 per share

Price / Book1.38

Profitability

EPS (Most Recent Fiscal Year)$15.15

Net Income$4.27 billion

Net Margins28.17%

Return on Equity14.19%

Return on Assets6.86%

Miscellaneous

Employees23,044

Outstanding Shares303,950,000

How to Become a New Pot Stock Millionaire

Shire (NASDAQ:SHPG) Frequently Asked Questions

What is Shire's stock symbol?

Shire trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire pay dividends? What is the dividend yield for Shire?

Shire declared a semiannual dividend on Friday, February 16th. Investors of record on Friday, March 9th will be given a dividend of $0.8937 per share on Tuesday, April 24th. This represents a dividend yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. This is a positive change from Shire's previous semiannual dividend of $0.15. View Shire's Dividend History.

How were Shire's earnings last quarter?

Shire (NASDAQ:SHPG) posted its earnings results on Thursday, April, 26th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Zacks' consensus estimate of $3.58 by $0.21. Shire had a return on equity of 14.19% and a net margin of 28.17%. View Shire's Earnings History.

When is Shire's next earnings date?

Shire is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Shire.

What guidance has Shire issued on next quarter's earnings?

Shire updated its FY18 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of $14.90-15.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.02. The company issued revenue guidance of 15.4-15.9 billion, compared to the consensus revenue estimate of $15.47 billion.

What price target have analysts set for SHPG?

16 equities research analysts have issued 12 month price objectives for Shire's shares. Their predictions range from $150.00 to $245.00. On average, they anticipate Shire's share price to reach $204.6429 in the next year. View Analyst Ratings for Shire.

What are Wall Street analysts saying about Shire stock?

Here are some recent quotes from research analysts about Shire stock:

1. Cantor Fitzgerald analysts commented, "Though it has not been confirmed by Shire yet, headlines from Reuters are reporting that Takeda (Not Covered) has made a takeover offer to Shire worth ~46.50 pounds/share (~$198 per ADS), which we estimate translates to ~ $61B (see Exhibit 1 on page 3 for details). Based on our conversations with shareholders, this seems like a reasonable starting price for a negotiation, but we think people will want to see $200+ unless it’s all cash." (4/16/2018)
2. According to Zacks Investment Research, "Sales of Shire’s Mydayis showed promise in the first six months of launch. Also, strong performance of Vyvanse, Cinryze and Elaprase continue to drive its top line. The label expansion of Firazyr in pediatrics and approval of Lyophilized Oncaspar in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. Though the adult ADHD space is one of the largest and fastest growing segments of the market, it is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past year. Estimates have remained stable ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/9/2018)
3. Royal Bank of Canada analysts commented, "We don’t have a clue on the contribution of PhotonBlade in the qtr. FY18 guidance will be critical. Consensus currently is ~$52M. A number below consensus will be parsed almost immediately as to implied PhotonBlade / non- PhotonBlade growth." (2/5/2018)

Who are some of Shire's key competitors?

Some companies that are related to Shire include GlaxoSmithKline (GSK), AstraZeneca (AZN), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN) and Grifols (GRFS).

Who are Shire's key executives?

Shire's management team includes the folowing people:

Dr. Flemming Ornskov M.P.H., MBA, M.D., MPH, CEO, MD & Exec. Director (Age 60)
Mr. Thomas J. W. Dittrich, CFO & Director (Age 54)
Gisele Dion, Chief Accounting Officer
Mr. Matthew Walker, Head of Technical Operations (Age 54)
Prof. Andreas Busch Ph.D., Head of R&D, Chief Scientific Officer & Exec. VP (Age 55)

Has Shire been receiving favorable news coverage?

News headlines about SHPG stock have trended positive on Sunday, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Shire earned a daily sentiment score of 0.28 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 43.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Shire?

Shares of SHPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Shire's stock price today?

One share of SHPG stock can currently be purchased for approximately $164.37.

How big of a company is Shire?

Shire has a market capitalization of $49.96 billion and generates $15.16 billion in revenue each year. The biopharmaceutical company earns $4.27 billion in net income (profit) each year or $15.15 on an earnings per share basis. Shire employs 23,044 workers across the globe.

How can I contact Shire?

Shire's mailing address is BLOCK 2 MIESIAN PLAZA 50-58 BAGGOT STREET LOWER, Dublin L2, D02. The biopharmaceutical company can be reached via phone at 353-1609-6000 or via email at [email protected]

MarketBeat Community Rating for Shire (SHPG)

Community Ranking:		3.4 out of 5 ( )
Outperform Votes:		899 (Vote Outperform)
Underperform Votes:		438 (Vote Underperform)
Total Votes:		1,337

MarketBeat's community ratings are surveys of what our community members think about Shire and other stocks. Vote "Outperform" if you believe SHPG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SHPG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Shire (NASDAQ:SHPG) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

16 Wall Street analysts have issued ratings and price targets for Shire in the last 12 months. Their average twelve-month price target is $204.6429, suggesting that the stock has a possible upside of 24.50%. The high price target for SHPG is $245.00 and the low price target for SHPG is $150.00. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.69	2.71	2.57	2.65
Ratings Breakdown:	0 Sell Rating(s) 5 Hold Rating(s) 11 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 5 Hold Rating(s) 12 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 6 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 7 Hold Rating(s) 13 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$204.6429	$204.00	$212.1818	$219.25
Price Target Upside:	24.50% upside	53.02% upside	34.90% upside	49.87% upside

Shire (NASDAQ:SHPG) Consensus Price Target History

Price Target History for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/19/2018	B. Riley	Boost Price Target	Buy	$200.00	Low
4/16/2018	Cantor Fitzgerald	Set Price Target	Buy	$222.00	Medium
3/28/2018	Bank of America	Reiterated Rating	Buy		High
2/20/2018	SunTrust Banks	Lower Price Target	Buy	$190.00	Medium
2/20/2018	JPMorgan Chase	Reiterated Rating	Overweight -> Neutral		Medium
2/16/2018	Royal Bank of Canada	Lower Price Target	Outperform	$181.00	Low
2/14/2018	Sanford C. Bernstein	Upgrade	Market Perform -> Outperform		Medium
1/5/2018	Cowen	Set Price Target	Buy	$225.00	Low
1/3/2018	Piper Jaffray	Reiterated Rating	Hold		Low
12/20/2017	Liberum Capital	Reiterated Rating	Buy -> Hold		Medium
10/30/2017	FBR & Co	Reiterated Rating	Buy	$201.00	N/A
10/8/2017	Stifel Nicolaus	Reiterated Rating	Buy	$245.00	N/A
8/16/2017	Evercore ISI	Initiated Coverage	Outperform -> Outperform	$196.00	Medium
8/11/2017	Barclays	Downgrade	Overweight -> Equal Weight		Low
8/9/2017	Jefferies Group	Reiterated Rating	Hold	$216.00 -> $206.00	Low
7/17/2017	BTIG Research	Reiterated Rating	Buy	$242.00	Low
4/17/2017	Goldman Sachs	Boost Price Target	Overweight	$202.00 -> $214.00	Low
2/17/2017	Guggenheim	Reiterated Rating	Neutral		N/A
12/6/2016	UBS	Downgrade	Buy -> Hold		N/A
12/2/2016	Societe Generale	Initiated Coverage	Buy		N/A
11/14/2016	Leerink Swann	Set Price Target	Buy	$198.00	N/A
11/3/2016	Citigroup	Reiterated Rating	Buy		N/A
11/2/2016	Deutsche Bank	Reiterated Rating	Buy		N/A
10/23/2016	BNP Paribas	Reiterated Rating	Buy		N/A
10/8/2016	Shore Capital	Reiterated Rating	Buy		N/A
6/3/2016	Morgan Stanley	Reiterated Rating	Overweight		N/A
5/23/2016	Bryan, Garnier & Co	Initiated Coverage	Buy		N/A

(Data available from 4/22/2016 forward)

Shire (NASDAQ:SHPG) Earnings History and Estimates Chart

Earnings by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Earnings Estimates

2018 EPS Consensus Estimate: $15.62

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	5	$3.54	$4.01	$3.81
Q2 2018	5	$3.63	$4.13	$3.85
Q3 2018	5	$3.71	$4.08	$3.84
Q4 2018	5	$3.78	$4.37	$4.12

Shire (NASDAQ SHPG) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
4/26/2018		$3.58	$3.37			View	N/A
2/14/2018	n/a	$3.86	$3.98		$4.1449 billion	View	N/A
10/27/2017	9/30/2017	$3.64	$3.81		$3.6976 billion	View	N/A
8/3/2017	6/30/2017	$3.53	$3.73		$3.7458 billion	View	Listen
5/2/2017	Q1 17	$3.22	$3.63		$3.5723 billion	View	Listen
2/16/2017	Q416	$3.24	$3.37	$3.7752 billion	$3.8061 billion	View	N/A
11/1/2016	Q316	$3.21	$3.17	$3.57 billion	$3.45 billion	View	N/A
8/2/2016	Q216	$3.03	$3.38	$2.2757 billion	$2.43 million	View	N/A
4/29/2016	Q1	$3.0540	$3.19	$1.71 billion	$1.71 billion	View	Listen
2/11/2016	Q415	$2.89	$2.97	$1.69 million	$1.7160 billion	View	Listen
10/23/2015	Q315	$2.87	$3.24	$1.63 billion	$1.58 billion	View	Listen
7/23/2015	Q215	$2.81	$2.63	$1.59 billion	$1.56 billion	View	Listen
4/30/2015	Q115	$2.56	$2.84	$1.47 billion	$1.49 billion	View	N/A
2/12/2015	Q115	$2.68	$2.63	$1.5293 billion	$1.5761 billion	View	N/A
10/24/2014	Q314	$2.47	$2.93	$1.46 billion	$1.55 billion	View	Listen
7/18/2014	Q214	$2.45	$2.67	$1.45 billion	$1.50 billion	View	N/A
5/1/2014	Q114	$2.22	$2.36	$1.38 billion	$1.35 billion	View	N/A
2/13/2014	Q413	$2.02	$2.26	$1.28 billion	$1.33 billion	View	N/A
10/24/2013	Q213	$1.65	$1.77	$1.23 billion	$1.24 billion	View	N/A
7/25/2013		$1.60	$1.79	$1.2146 billion	$1.2750 billion	View	N/A
5/2/2013	Q113	$1.56	$1.63	$1.21 billion	$1.16 billion	View	N/A
2/14/2013	Q412	$1.58	$1.58	$1.20 billion	$1.20 billion	View	N/A
10/25/2012		$1.47	$1.36			View	N/A
8/1/2012		$1.52	$1.68			View	N/A
4/26/2012		$0.52	$1.24			View	N/A
2/9/2012		$0.48	$0.44			View	N/A
10/28/2011		$1.31	$1.28			View	N/A
7/28/2011		$1.24	$1.33			View	N/A
4/28/2011		$1.18	$1.23			View	N/A
2/10/2011		$1.04	$1.03			View	N/A
10/29/2010	Q3 2010	$0.98	$1.16			View	N/A
8/4/2010	Q2 2010	$0.88	$1.03			View	N/A
4/29/2010	Q1 2010	$0.84	$1.01			View	N/A
2/19/2010	Q4 2009	$0.58	$1.10			View	N/A
10/30/2009	Q3 2009	$0.48	$0.49			View	N/A
8/5/2009	Q2 2009	$0.47	$0.60			View	N/A
4/30/2009	Q1 2009	$1.08	$1.28			View	N/A
2/19/2009	Q4 2008	$1.00	$1.01			View	N/A
10/29/2008	Q3 2008	$0.87	$1.17			View	N/A
7/31/2008	Q2 2008	$0.75	$0.95			View	N/A
4/25/2008	Q1 2008	$0.72	$0.74			View	N/A
2/21/2008	Q4 2007	$0.64	$0.94			View	N/A

(Earnings results data provided by Zacks Investment Research)

Shire (NASDAQ:SHPG) Dividend Information

Shire pays an annual dividend of $1.05 per share, with a dividend yield of 0.64%. SHPG's next semiannual dividend payment will be made on Tuesday, April 24. Shire pays out 6.93% of its earnings out as a dividend.

Next Dividend:	4/24/2018
Annual Dividend:	$1.05
Dividend Yield:	0.64%
Payout Ratio:	6.93% (Trailing 12 Months of Earnings) 6.90% (Based on This Year's Estimates) 6.43% (Based on Next Year's Estimates)

Dividend Payments by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ:SHPG) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/16/2018	semiannual	$0.8937	1.33%	3/8/2018	3/9/2018	4/24/2018
8/11/2017	semiannual	$0.1527	0.21%	9/7/2017	9/8/2017	10/20/2017
2/24/2017		$0.7710		3/8/2017	3/10/2017	4/25/2017
8/5/2016		$0.1390		9/7/2016	9/9/2016	10/7/2016
2/11/2016		$0.6650		3/9/2016	3/11/2016	4/12/2016
7/23/2015		$0.1263		9/2/2015	9/4/2015	10/2/2015
2/23/2015	semiannual	$0.5727	0.48%	3/11/2015	3/13/2015	4/14/2015
8/4/2014	semiannual	$0.1149	0.09%	9/3/2014	9/5/2014	10/3/2014
2/20/2014	semiannual	$0.5079	0.61%	3/5/2014	3/7/2014	4/8/2014
7/29/2013	semiannual	$0.09	0.16%	9/4/2013	9/6/2013	10/3/2013
2/19/2013	semiannual	$0.4380	0.92%	3/6/2013	3/8/2013	4/9/2013

(Data available from 1/1/2013 forward)

Shire (NASDAQ SHPG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 19.58%

Insider Trading History for Shire (NASDAQ:SHPG)

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Shire (NASDAQ SHPG) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details

(Data available from 1/1/2013 forward)

Shire (NASDAQ SHPG) News Headlines

Source:

Date	Headline
	Japan's Takeda sweetens $62 billion Shire offer www.reuters.com - April 22 at 8:14 AM
	Shire Rebuff May Not Dim Takeda's Appetite for $60 Billion Deal finance.yahoo.com - April 22 at 8:14 AM
	Shire (SHPG) Turns Down Takeda's Third Buyout Proposition finance.yahoo.com - April 22 at 8:14 AM
	Takeda's considering turning up the heat on its bid for Shire (TKPYY, SHPG) www.businessinsider.com - April 21 at 8:16 AM
	Takeda Adds More Cash in Boosting Shire Bid Over $60 Billion www.bloomberg.com - April 21 at 8:16 AM
	[$$] Takeda Increases Takeover Proposal for Drug Rival Shire finance.yahoo.com - April 21 at 8:16 AM
	Takeda sweetens offer for Shire to £47/share seekingalpha.com - April 20 at 10:28 AM
	Brainstorm Health: The Gene Testing Perk, Shire Takeover Drama, Marijuana-Based Epilepsy Drug fortune.com - April 20 at 8:20 AM
	Rare Disease Drug Maker Shire's Stock Spikes Amid Bidding War Between Allergan and Takeda fortune.com - April 20 at 8:20 AM
	Stocks to watch: Shire, Reckitt, Hammerson, Ericsson, Esure www.ft.com - April 20 at 8:20 AM
	Third Time Unlucky for Takeda and Shire www.wsj.com - April 20 at 8:20 AM
	'Losing direction': Allergan investors are unhappy after a wild 4-hour takeover drama www.businessinsider.com - April 20 at 8:20 AM
	Shire Rebuff May Not Dim Takeda's Appetite for a Takeover www.bloomberg.com - April 20 at 8:20 AM
	[$$] Shire shares down 3.7% after Allergan rules out bid finance.yahoo.com - April 20 at 8:19 AM
	Japan's Takeda shares drop as investors fret over Shire pursuit finance.yahoo.com - April 20 at 8:19 AM
	FTSE 100 rises, as pound falls on BOE rate-hike doubts finance.yahoo.com - April 20 at 8:19 AM
	Takeda slips after Shire rejects $63B offer seekingalpha.com - April 20 at 5:15 AM
	Shire says it rejected Takeda’s first three takeover offers, including $60B bid www.bizjournals.com - April 19 at 5:44 PM
	Takeda Says Shire (SHPG) Rejected GBP 46.50 per Share Offer www.streetinsider.com - April 19 at 5:44 PM
	CNBC: Allergan-Shire Deal Is DOA finance.yahoo.com - April 19 at 5:44 PM
	Is Shire plc’s (NASDAQ:SHPG) PE Ratio A Signal To Buy For Investors? finance.yahoo.com - April 19 at 5:44 PM
	Shire (SHPG) Comments on Proposals from Takeda Pharmaceutical www.streetinsider.com - April 19 at 5:44 PM
	B. Riley Increases Shire (SHPG) Price Target to $200.00 www.americanbankingnews.com - April 19 at 3:33 PM
	Allergan will not bid for Shire: Sources www.cnbc.com - April 19 at 1:19 PM
	Shire (SHPG) Given a $222.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - April 19 at 12:16 PM
	AbbVie down 2% on investor concerns with potential interest in Shire seekingalpha.com - April 19 at 12:07 PM
	Stocks to watch: Weir, Shire, Publicis, Ultra Electronics, WPP www.ft.com - April 19 at 8:12 AM
	Takeda Offers About $60 Billion for Shire, Reuters Says www.bloomberg.com - April 19 at 8:12 AM
	[$$] Takeda makes £42.4bn bid for Shire finance.yahoo.com - April 19 at 8:11 AM
	Takeda makes $61 billion bid for drugmaker Shire - sources finance.yahoo.com - April 19 at 8:11 AM
	Brokers Issue Forecasts for Shire's Q1 2018 Earnings (SHPG) www.americanbankingnews.com - April 19 at 5:58 AM
	Shire (SHPG) to Release Earnings on Thursday www.americanbankingnews.com - April 19 at 2:52 AM
	FY2019 Earnings Forecast for Shire (SHPG) Issued By SunTrust Banks www.americanbankingnews.com - April 18 at 8:52 AM
	FDA OKs expanded use for Shire's Vonvendi; shares up 2% premarket seekingalpha.com - April 17 at 10:12 AM
	Shire plc : FDA APPROVES VONVENDI® FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE feeds.benzinga.com - April 17 at 9:51 AM
	On World Hemophilia Day 2018, Shire Unites Communities in Asia Pacific and Advocates for 'Principles of Care' finance.yahoo.com - April 17 at 8:24 AM
	Shire (SHPG) Downgraded by BidaskClub to "Strong Sell" www.americanbankingnews.com - April 16 at 11:29 PM
	Cantor Fitzgerald Analysts Give Shire (SHPG) a $222.00 Price Target www.americanbankingnews.com - April 16 at 8:18 AM
	BRIEF-Shire Sells Oncology Business To Servier For $2.4 Billion www.reuters.com - April 16 at 8:12 AM
	Sorrell Out, Shire Slims, Data Monopolies: CEO Daily for April 16, 2018 fortune.com - April 16 at 8:12 AM
	Shire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls Takeover www.wsj.com - April 16 at 8:12 AM
	Shire's $2.4 Billion Cancer-Unit Sale Sweetens Takeda Appeal finance.yahoo.com - April 16 at 8:12 AM
	Shire to Sell Oncology Business to Servier for $2.4 Billion finance.yahoo.com - April 16 at 8:12 AM
	[$$] Shire to Sell Oncology Unit for $2.40 Billion finance.yahoo.com - April 16 at 8:12 AM
	Shire to sell oncology unit to Servier for $2.4 billion finance.yahoo.com - April 16 at 8:12 AM
	[$$] Shire sells oncology unit to France’s Servier for $2.4bn finance.yahoo.com - April 16 at 8:12 AM
	FTSE 100 pulled lower by slump for WPP finance.yahoo.com - April 16 at 8:12 AM
	[$$] Shire to Sell Oncology Unit as Takeda Mulls Takeover finance.yahoo.com - April 16 at 8:12 AM
	Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles finance.yahoo.com - April 16 at 8:12 AM
	Shire sells oncology unit for £1.7bn as Takeda boss prepares potential bid uk.finance.yahoo.com - April 16 at 8:12 AM